Skip directly to content

HIV PROJECT PUBLICATIONS

TAGline
NEWS ON THE FIGHT FOR BETTER TREATMENT, A VACCINE, AND A CURE FOR AIDS

Community Mobilization: An Assessment of Mechanisms and Barriers at Community-Based and AIDS Service Organizations in Nine U.S. Metropolitan Areas
January 9, 2017 – New Report Shines Spotlight on Need for More Investments in Community Leadership and Mobilization to End HIV as an Epidemic

2016 Pipeline Report
July 15, 2016 – HIV and TB Drugs, Diagnostics, Vaccines, Preventive Technologies, Research Toward a Cure, and Immune-Based and Gene Therapies in Development

2015 Pipeline Report
July 17, 2015 – HIV, HCV, and TB Drugs, Diagnostics, Vaccines, Preventive Technologies, Research Toward a Cure, and Immune-Based and Gene Therapies in Development

Toward Comprehensive HIV Prevention Service Delivery in the United States: An Action Plan
June 24, 2015 – An objective of the National HIV/AIDS Strategy (NHAS), released by the White House in July 2010, is to lower the annual number of new infections in the United States by 25 percent by the end of 2015. Yet it is unclear if we will succeed in meeting this arguably unambitious target: 36,400 estimated new infections in 2015, compared with the 48,600 new infections estimated for the baseline year of 2006.

The Immune System, HIV, and Aging
June 3, 2013 – Little more than a decade ago, it was almost inconceivable that the issue of aging with HIV infection would emerge as an important concern. But it has now become clear that combination antiretroviral therapy (ART) can suppress virus replication for many years—likely for life—in most people who can access the drugs, and the opportunistic infections that were once the primary causes of illness have largely evanesced everywhere treatment is available. Morbidity and mortality from HIV infection has plummeted, and the survival of HIV-positive individuals is edging ever closer to that of comparable HIV-negative people. With the specter of AIDS having finally been chased from the near horizon, attention has turned to health problems that may lie further down the road.

Revitalizing the U.S. National HIV/AIDS Strategy
Meeting Report and Action Plan
April 15, 2013 – On December 11–12, 2012, in Washington, D.C., Treatment Action Group (TAG) hosted a meeting of HIV advocates, service providers, and researchers from across the United States (U.S.) to review the current state of the national HIV response and discuss how to revitalize the National HIV/AIDS Strategy (NHAS). Meeting participants reviewed the latest data, discussed the changing landscape of the HIV response, and developed recommendations for continued and expedited progress. The Meeting Report summarizes the presentations and discussions, and outlines the key recommendations from participants. The Action Plan incorporates the recommendations from the meeting report.

Funding Scientific Innovation: Global Investments in HIV Treatment Research and Development in 2010 and 2011
March 6, 2013 – Advances in HIV treatment research in 2010 and 2011 saw improvement in treatment regimens and strategies, and reinvigorated optimism for finding a cure. In 2012, TAG and AVAC, with financial support from UNAIDS, put forth a collaborative effort to analyze investment trends in HIV treatment research and development (R&D) in 2010 and 2011.

2012 PIPELINE REPORT
HIV, Hepatitis C Virus (HCV), and Tuberculosis (TB) Drugs, Diagnostics, Vaccines, and Preventive Technologies in Development
July 22, 2012 - Visit our new website www.PipelineReport.org to:

  • Read the report online
  • Download individual chapters as PDFs
  • Browse for specific information by agent

HIV Cure-Related Research Workshop Report
October 2011 – The meeting, sponsored by the AIDS Policy Project, amfAR, Project Inform, and TAG, featured an overview of HIV latency, persistence, and eradication research; lessons from past clinical trials; a review of current or impending trials; and a full discussion of issues including trial design, appropriate markers and endpoints, and development of better assays. Participants heard a presentation on the ethics of clinical trials and discussed the federal regulatory process and how best to engage the several branches of the U.S. Food and Drug Administration (FDA) in a coordinated and collaborative way to work together to ensure that cure-related clinical trials proceed expeditiously, ethically, and safely.

2011 Pipeline Report - Second Edition
September 2011 – HIV, Hepatitis C Virus (HCV), and Tuberculosis Drugs, Diagnostics, Vaccines, and Preventive Technologies in Development.

AIDS Research: Broad Health and Economic Benefits
July 2011 – Investments in health research at the National Institutes of Health (NIH) have paid enormous dividends in the health and well-being of people in the U.S. and around the world. HIV and AIDS research supported by NIH has yielded important recent advances and holds great promise for significantly reducing HIV infection rates and providing more effective treatments for people living with HIV/AIDS.

An Exploratory Analysis of HIV Treatment Research and Development Investments in 2009
July 2011 – The HIV treatment research landscape is changing. Thanks to recent treatment scale-up and prevention science breakthroughs and the new global treatment target of 15 million by 2015, there is real momentum to bring the epidemic under control and ultimately end it. To capitalize on these scientific gains, continued investment and innovation are necessary to prevent new infections, to ensure people currently on treatment are able to continue, and to scale up treatment to reach all those who will benefit from earlier initiation of antiretroviral therapy. This report from TAG, UNAIDS, and the AIDS Vaccine Advocacy Coalition documents $2.46 billion in HIV-related research investments.

Clinical Trials for People with Suboptimal Immune Reconstitution Despite HIV Suppression
June 2011 – Some individuals who initiate antiretroviral therapy (ART) experience limited recovery of CD4 T cell numbers despite suppression of HIV viral load to undetectable levels. The most common risk factors for this type of discordant response to ART are low CD4 T cell count at the time of starting and older age. Individuals in this situation still experience a benefit from ART in terms of a greatly reduced risk of opportunistic infections, illness and death, but their risk of these outcomes is higher than among people with greater CD4 T cells gains. For this reason, a number of clinical trials are investigating approaches that might boost CD4 T cell recovery in individuals whose CD4 T cell counts remain relatively low despite viral load suppression. The purpose of this page is to provide a resource listing of these clinical trials, which will be updated on an ongoing basis.

Letter to Dr. Fauci to Support HIV and Aging Research
September 20, 2010 – The many complications and comorbidities faced by the aging population of HIV positive people in the United States constitute a rapidly growing medical crisis that has been woefully neglected by U.S. research efforts. According to the Centers for Disease Control, more than half of all HIV-positive Americans will be over the age of 50 by or before the year 2015. Although increasing evidence points to an earlier onset of age related conditions in people living with HIV little is known about pathogenesis, or proper methods to screen for, prevent and manage these conditions, or anticipate the infrastructure needed to deliver care and treatment for people suffering from these conditions.

Mark Harrington at AIDS 2010 from Vienna (Video)
Starting HAART: When to Take the First Step?

July 20, 2010 – Recent guidelines are all recommending that HIV treatment be started at a higher CD4 count because of issues such as the ongoing damage caused by HIV itself, and prevention of transmission. Issues in long-term treatment, such as potential side effects, the development of resistance, the cost and sustainability of programmes in resource-poor settings, are some of the potential problems for such a strategy. This session discussed the pros and cons of early initiation and highlighted areas of controversy and agreement.

TAG Featured in POZ Magazine
April 1, 2010 – Mark Harrington, founding member and executive director of Treatment Action Group (TAG), a giant in the world of HIV/AIDS treatment and advocacy, can boast about many accomplishments: his paradigm-shifting work on the Treatment and Data committee of the AIDS Coalition to Unleash Power (ACT UP), 18 years of continued achievements at TAG, countless scientific articles and speaking engagements, membership on various U.N. advisory committees, even a MacArthur “Genius” grant in 1997.

Issue Brief: A Sound Investment: The Multiplier Effect of AIDS Research
March 2010 – Investments in health research at the National Institutes of Health (NIH) have paid enormous dividends in the health and well-being of people in the U.S. and around the world. HIV and AIDS research supported by NIH has saved and improved the lives of millions and holds great promise for significantly reducing HIV infection rates and providing more effective treatments for those living with HIV/AIDS. Yet years of erratic funding levels for NIH have undermined our nation’s leadership in health research and our scientists’ ability to take advantage of the expand-ing opportunities to advance healthcare. The race to find better treatments and cures for cancer, heart disease, AIDS, and other diseases—and to control global epidemics such as AIDS, tuberculosis, and malaria—depends on robust long-term investment in health research at NIH.

TAG Mourns the Loss of Dennis deLeon
New York, December 14, 2009 – Treatment Action Group (TAG), the New York-based AIDS research and policy think tank, issued this statement today upon the death of Dennis deLeon, long-time Executive Director of the Latino AIDS Commission and former New York City Commissioner of Human Rights.

PRESIDENT OBAMA’S WORLD AIDS DAY REPORT CARD: EMERGENCY COURSE CORRECTION REQUIRED
Assessing President Obama’s Response to the Global AIDS Crisis
December 1, 2009, marks President Obama’s first World AIDS Day in the White House and the first World AIDS Day for the newly elected Congress. The time is right for a frank assessment of his first year in the fight against global AIDS as President. This analysis focuses on the funding and policy decisions the Administration has made since taking office in January 2009, and assesses the human impact of those decisions.

The Future of Global Health: Ingredients for a Bold & Effective U.S. Initiative
October 2009 – Major accomplishments in global health over the last decade demonstrate that adequately resourced programs, focused on achieving specific results, can improve health outcomes for millions and support economic progress. They also show that distinct public health challenges are closely interconnected and that a comprehensive and integrated strategy is needed to ensure that ambitious health goals are met.

2009 Pipeline Report
HIV, Tuberculosis, and Viral Hepatitis: Drugs, Diagnostics, Vaccines, and Microbicides in Development

July 2009 -–TAG’s annual Pipeline Reportsurveys the developments in medicines and diagnostics most likely to improve the lives of people living with HIV, viral hepatitis, and tuberculosis within the next few years. But in spotlighting what is in the pipeline, the report also identifies critical gaps where research is falling short of the need for better tools to manage these diseases.

Workshop Report: Studying the Impact of Genetic Variation on the Host Response to HIV
July 10, 2009 – On January 8, the Office of AIDS Research convened a two-day workshop to discuss genome-wide association scan (GWAS) studies in HIV infection. GWAS involve studying known variations in the human genetic code (called single nucleotide polymorphisms or SNPs) to find out if these variants impact an outcome of interest, such as the rate of disease progression in HIV-infected individuals. The overall goal of the workshop was to prioritize which facets of HIV infection should be investigated using the GWAS approach, as in addition to evaluating outcomes involving disease progression there are many other possibilities, such as looking for associations with resistance to HIV infection among individuals who remain seronegative despite repeated exposures to the virus. The workshop also discussed key issues related to the conduct of GWAS studies, such as the availability of appropriate cohorts and control groups, and the question of whether potential cohorts have appropriate samples and informed consent.

Flat-Lined: How Flat NIH Funding Undermines Research on HIV, Tuberculosis, and Viral Hepatitis
May 2009 – The goal of this funding analysis is to provide a comprehensive picture of the current state of U.S. National Institutes of Health (NIH) research investment in HIV/AIDS and three of its most common coinfections—hepatitis B virus (HBV), hepatitis C virus (HCV), and tuberculosis (TB)—after five years of flat funding at the NIH (2004– 2009).

TAG Calls on Obama Administration to Revitalize the World's Fight Against HIV and AIDS
April 27, 2009 – Treatment Action Group (TAG), the nation’s only organization focused exclusively on fighting for better treatments, a cure, and a vaccine for AIDS, today welcomed the Obama administration’s nomination of Dr. Eric Goosby as the next Global AIDS Coordinator in the State Department, which administers the President’s Emergency Plan for AIDS Relief (PEPFAR), the world’s largest international HIV/AIDS prevention and treatment program.

Letter to NIAID Director Anthony Fauci Opposing the HVTN 505 Vaccine Trial
April 7, 2009 – TAG has previously expressed opposition to the PAVE100A vaccine trial involving the Vaccine Research Center’s DNA and Ad5 candidate(i). With the recent presentation by Dan Barouch of new macaque challenge data involving a DNA/adenovirus prime-boost regimen at the 2009 Keystone meeting(ii), we now must vociferously oppose the proposed descendant of PAVE100A, the HVTN 505 trial.

For older publications, please go to the publications page.